Overview

A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A

Status:
Withdrawn
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 4 clinical trial to treat patients who have failed to treat with regimen based on an inhibitor of the NS5A
Phase:
Phase 4
Details
Lead Sponsor:
Fundacion SEIMC-GESIDA
Treatments:
Grazoprevir
Ribavirin
Sofosbuvir